Limitations and Future Studies Several limitations of our NMA should be stated
Therefore, drugs that are able to down-regulate the activity of GSK-3 hold high promise of therapeutic effects for aging-related diseases
"GLP-1 receptor agonist use was associated with a higher risk of clinically recorded alopecia, particularly non-scarring alopecia, in patients with type 2 diabetes, compared with SGLT-2 and DPP-4 inhibitors," write the researchers in their published paper
That is why a single peptide rarely delivers what people expect
A 2021 analysis of semaglutide clinical trials found an increased risk of DVTs in patients who took the drug
Unlike Melanotan II, PT-141 does not meaningfully stimulate MC1R, meaning it generally does not cause skin darkening